Stock SYNT SYNTHETICMR AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SyntheticMR AB

Equities

SYNT

SE0015987946

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-01-30 pm EST 		5-day change 1st Jan Change
27.7 SEK +1.09% Intraday chart for SyntheticMR AB -.--% +4.14%
Apr. 17 SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities CI
Mar. 27 SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

  • With an expected P/E ratio at 50.52 and 29.24 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
SYNTHETICMR AB Stock SyntheticMR AB
+4.14% 105M
D
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
C-
SECTRA AB Stock Sectra AB
+22.93% 3.89B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M -
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M -
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. SYNT Stock
  4. Ratings SyntheticMR AB